A lack of 12-month endometrial safety data led to the FDA's rejection of an NDA filed by Therapeuticsmd Inc. for Yuvvexy, an investigational treatment of moderate to severe vaginal pain during sex. The complete response letter (CRL) for the 505(b)(2) application arrived on the heels of the regulator alerting the company to an unspecified deficiency in its application last month.